5a-Androstane-3a,17b-diol (3a-diol) is reduced from the potent androgen, 5a-dihydrotestosterone (5a-DHT), by reductive 3a-hydroxysteroid dehydrogenases (3a-HSDs) in the prostate. 3a-diol is recognized as a weak androgen with low affinity toward the androgen receptor (AR), but can be oxidized back to 5a-DHT. However, 3a-diol may have potent effects by activating cytoplasmic signaling pathways, stimulating AR-independent prostate cell growth, and, more importantly, providing a key signal for androgen-independent prostate cancer progression. A cancer-specific, cDNAbased membrane array was used to determine 3a-diol-activated pathways in regulating prostate cancer cell survival and/or proliferation. Several canonical pathways appeared to be affected by 3a-diol-regulated responses in LNCaP cells; among them are apoptosis signaling, PI3K/AKT signaling, and death receptor signaling pathways. Biological analysis confirmed that 3a-diol stimulates AKT activation; and the AKT pathway can be activated independent of the classical AR signaling. These observations sustained our previous observations that 3a-diol continues to support prostate cell survival and proliferation regardless the status of the AR. We provided the first systems biology approach to demonstrate that 3a-diol-activated cytoplasmic signaling pathways are important components of androgen-activated biological functions in human prostate cells. Based on the observations that levels of reductive 3a-HSD expression are significantly elevated in localized and advanced prostate cancer, 3a-diol may, therefore, play a critical role for the transition from androgen-dependent to androgen-independent prostate cancer in the presence of androgen deprivation.